Q-omics provides the consensus-scored TTC13 profile across patient tissues and cancer cell-line models. TTC13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TTC13 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TTC13 RNA expression shows 20,412 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where TTC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC13 survival associations across molecular data types. TTC13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC13 RNA expression–survival associations across cancer types. High TTC13 expression shows unfavorable associations in KIRP, ACC, LIHC, KIRC and UVM, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TTC13 RNA expression.
This table summarizes TTC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC13 shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, STAD and LUAD. The HNSC box plot shows higher TTC13 RNA expression in tumor versus normal tissue (log2 FC = +1.021, t-test p < 0.001).
This table shows molecular features associated with TTC13 in patient tissues and cancer cell lines. In patient samples, TTC13 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
